The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.
The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.
हिन्दी 
English